Last reviewed · How we verify
NCT01639391: ALSCELL
Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study
NA trial testing skin biopsy in Amyotrophic Lateral Sclerosis in 19 participants. Completed in 17 March 2015.
17 March 2015
Quick facts
| Lead sponsor | Institut Pasteur |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 19 |
| Start date | 29 November 2012 |
| Primary completion | 17 March 2015 |
| Estimated completion | 17 March 2015 |
| Sites | 1 location across France |
Drugs / interventions tested
- skin biopsy
Conditions studied
- Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →
Sponsor
Institut Pasteur — full company profile →
Who can join
18 and older, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with ALS will be included in the reference center for ALS in hospital La Pitié Salpêtrière, Paris. The study proposes to investigate the pathophysiology of ALS by setting up a fibroblast bank for studying molecular, cellular and genetic parameters of the pathology. iPS (induced pluripotent stem cells) and then differentiated cells will be generated. The pathophysiology of ALS will be studied on the 3 types of cells (fibroblasts, iPS, differentiated cells).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Electrical Stimulation Promotes Stem Cell Neural Differentiation in Tissue Engineering.
Cheng H, Huang Y, Yue H, Fan Y. · · 2021 · cited 66× · PMID 33968150 · DOI 10.1155/2021/6697574 -
Stem cell transplantation in neurological diseases: improving effectiveness in animal models.
Adami R, Scesa G, Bottai D. · · 2014 · cited 27× · PMID 25364724 · DOI 10.3389/fcell.2014.00017 -
iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine.
Pandey S, Jirásko M, Lochman J, Chvátal A, et al · · 2022 · cited 17× · PMID 36143270 · DOI 10.3390/jpm12091485 -
Cell Transdifferentiation and Reprogramming in Disease Modeling: Insights into the Neuronal and Cardiac Disease Models and Current Translational Strategies.
Kalra RS, Dhanjal JK, Das M, Singh B, et al · · 2021 · cited 16× · PMID 34685537 · DOI 10.3390/cells10102558
Verify or expand the search:
- PubMed search for NCT01639391
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of skin biopsy
Trials testing the same drug.
- NCT07075107 — Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases · NA · not yet recruiting
- NCT06444217 — Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD · NA · recruiting
- NCT06792487 — Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23) · recruiting
- NCT06336473 — Evaluation of the Effects of Cross Linking on the Biomechanical Characteristics of Skin Samples From Patients With Class · NA · not yet recruiting
- NCT06050330 — CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study · NA · completed
Other recruiting trials for Amyotrophic Lateral Sclerosis
Currently open trials in the same condition.
- NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
- NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
- NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting
Other Institut Pasteur trials
Trials by the same sponsor.
- NCT07205913 — Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND · not yet recruiting
- NCT06945822 — Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI · NA · not yet recruiting
- NCT05821478 — Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients · Phase 3 · recruiting
- NCT06769815 — Host Immunity, Plasmodium and Pathogens Co-Infections · NA · not yet recruiting
- NCT06718127 — Description of the Immune Response to Yellow Fever Vaccination · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01639391 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Pasteur
- Last refreshed: 1 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01639391.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing